Leucid Bio to Participate in Upcoming Healthcare Conferences

Leucid Bio is a biotechnology company developing novel, Lateral CAR cell therapies for the treatment of refractory cancers. Leucid was established to translate 20 years of King's College London research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Leucid is headquartered in London, UK, with operations based at Guy's Hospital, which enables the Company to maintain its patient-centric focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumours. For more information, please visit the Leucid Bio website at https://www.leucid.com/.

Leucid Bio is a biotechnology company developing novel, Lateral CAR cell therapies for the treatment of refractory cancers. Leucid was established to translate 20 years of King's College London research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Leucid is headquartered in London, UK, with operations based at Guy's Hospital, which enables the Company to maintain its patient-centric focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumours. For more information, please visit the Leucid Bio website at https://www.leucid.com/.

View original content:https://www.prnewswire.co.uk/news-releases/leucid-bio-to-participate-in-upcoming-healthcare-conferences-301971690.html